Andamento 4503.T · Astellas Pharma Inc.
Cosa dice MarketSider oggi
Chi è Astellas Pharma Inc.
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Valutazione
Redditività
Crescita
Solidità Finanziaria
Dividendi
Cosa ne pensano gli analisti
Approfondisci i fondamentali
Analisi tecnica AI — 01 settembre 2026
RSI (14) — Zona neutrale57▾
MACD — Momentum rialzista forte47.26▾
Performance oggi — Seduta positiva+1.81%▾
Volume — Volume nella norma5.7M▾
Sentiment AI notizie — Neutro0▾
Continua a imparare
Titoli correlati — Farmaceutico
18 in evidenza ora (selezione per movimento) · 48 nel settore
Ultime notizie su Astellas Pharma Inc.
Nessuna notizia recente su Astellas Pharma Inc.
Le notizie vengono aggiornate ogni 2 ore dalla pipeline AI.
Vai alle ultime notizieAnalisi approfondita su Astellas Pharma Inc.: target price, rischi, opportunità e confronto competitor.